CL2009000368A1 - 3-(amido o sulfamido)-4-(4-azinil sustituido) benzamidas o benzosulfonamidas; la composicion farmaceutica que los contiene; el uso de los compuestos; y un kit que contiene dichos compeustos; utiles como inhibidores del receptor de quimioquinas cxcr3. - Google Patents
3-(amido o sulfamido)-4-(4-azinil sustituido) benzamidas o benzosulfonamidas; la composicion farmaceutica que los contiene; el uso de los compuestos; y un kit que contiene dichos compeustos; utiles como inhibidores del receptor de quimioquinas cxcr3.Info
- Publication number
- CL2009000368A1 CL2009000368A1 CL2009000368A CL2009000368A CL2009000368A1 CL 2009000368 A1 CL2009000368 A1 CL 2009000368A1 CL 2009000368 A CL2009000368 A CL 2009000368A CL 2009000368 A CL2009000368 A CL 2009000368A CL 2009000368 A1 CL2009000368 A1 CL 2009000368A1
- Authority
- CL
- Chile
- Prior art keywords
- benzosulfonamides
- benzamides
- sulfonamido
- amido
- inhibitors
- Prior art date
Links
- 125000003368 amide group Chemical group 0.000 title abstract 2
- 229940054066 benzamide antipsychotics Drugs 0.000 title abstract 2
- 150000003936 benzamides Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 title abstract 2
- 101150004010 CXCR3 gene Proteins 0.000 title 1
- 102000003675 cytokine receptors Human genes 0.000 abstract 1
- 108010057085 cytokine receptors Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2973808P | 2008-02-19 | 2008-02-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2009000368A1 true CL2009000368A1 (es) | 2009-06-26 |
Family
ID=40527535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2009000368A CL2009000368A1 (es) | 2008-02-19 | 2009-02-18 | 3-(amido o sulfamido)-4-(4-azinil sustituido) benzamidas o benzosulfonamidas; la composicion farmaceutica que los contiene; el uso de los compuestos; y un kit que contiene dichos compeustos; utiles como inhibidores del receptor de quimioquinas cxcr3. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8268828B2 (enExample) |
| EP (1) | EP2262784B1 (enExample) |
| JP (1) | JP2011512412A (enExample) |
| KR (1) | KR20100123835A (enExample) |
| CN (1) | CN102007108A (enExample) |
| AR (1) | AR070430A1 (enExample) |
| AU (1) | AU2009215643A1 (enExample) |
| BR (1) | BRPI0908815A2 (enExample) |
| CA (1) | CA2715557A1 (enExample) |
| CL (1) | CL2009000368A1 (enExample) |
| CO (1) | CO6241113A2 (enExample) |
| CR (1) | CR11604A (enExample) |
| DO (1) | DOP2010000254A (enExample) |
| EC (1) | ECSP10010409A (enExample) |
| IL (1) | IL207597A0 (enExample) |
| MA (1) | MA32191B1 (enExample) |
| MX (1) | MX2010008397A (enExample) |
| NI (1) | NI201000132A (enExample) |
| NZ (1) | NZ587380A (enExample) |
| PE (1) | PE20091576A1 (enExample) |
| RU (1) | RU2010138577A (enExample) |
| SV (1) | SV2010003648A (enExample) |
| TW (1) | TW200948791A (enExample) |
| WO (1) | WO2009105435A1 (enExample) |
| ZA (1) | ZA201005314B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20091576A1 (es) | 2008-02-19 | 2009-11-05 | Sanofi Aventis | DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3 |
| JP5807971B2 (ja) | 2009-04-27 | 2015-11-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｘｃｒ３受容体アンタゴニスト |
| US8952004B2 (en) | 2010-01-07 | 2015-02-10 | Boehringer Ingelheim International Gmbh | CXCR3 receptor antagonists |
| KR101251788B1 (ko) | 2010-12-06 | 2013-04-08 | 기아자동차주식회사 | 차량 연비 정보 단말표시 시스템 및 그 방법 |
| JP6162694B2 (ja) | 2011-07-18 | 2017-07-12 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ベンズアミド類 |
| EP2601950A1 (en) | 2011-12-06 | 2013-06-12 | Sanofi | Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists |
| CN104080784B (zh) * | 2012-01-10 | 2017-07-18 | 默克专利有限公司 | 用作卵泡刺激素调节剂的苯甲酰胺衍生物 |
| EP2809668B1 (en) | 2012-02-02 | 2017-04-12 | Actelion Pharmaceuticals Ltd. | 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives |
| EP2666769A1 (en) | 2012-05-23 | 2013-11-27 | Sanofi | Substituted B-amino acid derivatives as CXCR3 receptor antagonist |
| SG11201600504TA (en) | 2013-07-22 | 2016-02-26 | Actelion Pharmaceuticals Ltd | 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives |
| AR099789A1 (es) | 2014-03-24 | 2016-08-17 | Actelion Pharmaceuticals Ltd | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina |
| US10266526B2 (en) * | 2014-09-10 | 2019-04-23 | Epizyme, Inc. | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer |
| AR103399A1 (es) | 2015-01-15 | 2017-05-10 | Actelion Pharmaceuticals Ltd | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3 |
| TWI693221B (zh) | 2015-01-15 | 2020-05-11 | 瑞士商愛杜西亞製藥有限公司 | 作為ｃｘｃｒ３受體調節劑之羥烷基六氫吡衍生物 |
| CA3054945A1 (en) * | 2017-03-26 | 2018-10-04 | Takeda Pharmaceutical Company Limited | Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of gpr6 |
| CN115974766B (zh) * | 2023-01-04 | 2025-05-16 | 中国药科大学 | N-苄基-3-苯基酰胺类衍生物、包含其的药物组合物及其应用 |
| CN116410159B (zh) * | 2023-06-09 | 2023-08-22 | 济南国鼎医药科技有限公司 | 一种恩曲替尼中间体的制备方法及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3719660A (en) | 1969-06-13 | 1973-03-06 | Takeda Chemical Industries Ltd | 2-furfurylthioinosine-5'-phosphate compounds |
| US3840556A (en) | 1971-05-28 | 1974-10-08 | Lilly Co Eli | Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby |
| US6124319A (en) | 1997-01-21 | 2000-09-26 | Merck & Co., Inc. | 3,3-disubstituted piperidines as modulators of chemokine receptor activity |
| US6469002B1 (en) | 2001-04-19 | 2002-10-22 | Millennium Pharmaceuticals, Inc. | Imidazolidine compounds |
| US6794379B2 (en) | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
| GB0203994D0 (en) | 2002-02-20 | 2002-04-03 | Celltech R&D Ltd | Chemical compounds |
| EP1554253A4 (en) | 2002-06-03 | 2006-09-20 | Smithkline Beecham Corp | IMIDAZOLIUM COMPOUNDS INHIBITORS OF CXCR3 |
| US6734659B1 (en) | 2002-06-13 | 2004-05-11 | Mykrolis Corporation | Electronic interface for use with dual electrode capacitance diaphragm gauges |
| CN101146793A (zh) * | 2005-02-16 | 2008-03-19 | 先灵公司 | 具有cxcr3拮抗剂活性的新的杂环取代了的吡啶或苯基化合物 |
| MX2007009946A (es) * | 2005-02-16 | 2007-09-26 | Schering Corp | Piperazin-piperidinas sustituidas con piridilo y fenilo con actividad antagonista de cxcr3. |
| EP1856098B1 (en) | 2005-02-16 | 2012-08-01 | Schering Corporation | Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity |
| US20080312215A1 (en) * | 2005-06-28 | 2008-12-18 | Pharmacopeia Drug Discovery, Inc. | Substituted [1,4]-diazepanes as CXCR3 antagonists and their use in the treatment of inflammatory disorders |
| US7781437B2 (en) | 2005-10-11 | 2010-08-24 | Schering Corporation | Substituted heterocyclic compounds with CXCR3 antagonist activity |
| US20090143413A1 (en) | 2005-11-29 | 2009-06-04 | Adams Alan D | Thiazole Derivatives as CXCR3 Receptor Modulators |
| AU2007227425A1 (en) | 2006-03-21 | 2007-09-27 | Pharmacopeia, Inc. | Heterocyclic substituted pyridine compounds with CXCR3 antagonist activity |
| US7902199B2 (en) | 2006-07-14 | 2011-03-08 | Schering Corporation | Heterocyclic substituted piperazine compounds with CXCR3 antagonist activity |
| PE20091576A1 (es) | 2008-02-19 | 2009-11-05 | Sanofi Aventis | DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3 |
-
2009
- 2009-02-17 PE PE2009000232A patent/PE20091576A1/es not_active Application Discontinuation
- 2009-02-18 CN CN2009801138321A patent/CN102007108A/zh active Pending
- 2009-02-18 CA CA2715557A patent/CA2715557A1/en not_active Abandoned
- 2009-02-18 EP EP09711984.6A patent/EP2262784B1/en active Active
- 2009-02-18 AU AU2009215643A patent/AU2009215643A1/en not_active Abandoned
- 2009-02-18 JP JP2010547712A patent/JP2011512412A/ja active Pending
- 2009-02-18 AR ARP090100561A patent/AR070430A1/es not_active Application Discontinuation
- 2009-02-18 NZ NZ587380A patent/NZ587380A/en not_active IP Right Cessation
- 2009-02-18 MX MX2010008397A patent/MX2010008397A/es not_active Application Discontinuation
- 2009-02-18 KR KR1020107018467A patent/KR20100123835A/ko not_active Withdrawn
- 2009-02-18 BR BRPI0908815A patent/BRPI0908815A2/pt not_active IP Right Cessation
- 2009-02-18 WO PCT/US2009/034340 patent/WO2009105435A1/en not_active Ceased
- 2009-02-18 RU RU2010138577/04A patent/RU2010138577A/ru not_active Application Discontinuation
- 2009-02-18 CL CL2009000368A patent/CL2009000368A1/es unknown
- 2009-02-19 TW TW098105199A patent/TW200948791A/zh unknown
-
2010
- 2010-07-26 ZA ZA2010/05314A patent/ZA201005314B/en unknown
- 2010-07-28 CR CR11604A patent/CR11604A/es not_active Application Discontinuation
- 2010-07-29 NI NI201000132A patent/NI201000132A/es unknown
- 2010-08-06 US US12/852,076 patent/US8268828B2/en active Active
- 2010-08-12 IL IL207597A patent/IL207597A0/en unknown
- 2010-08-18 EC EC2010010409A patent/ECSP10010409A/es unknown
- 2010-08-18 DO DO2010000254A patent/DOP2010000254A/es unknown
- 2010-08-18 SV SV2010003648A patent/SV2010003648A/es not_active Application Discontinuation
- 2010-08-19 CO CO10102315A patent/CO6241113A2/es not_active Application Discontinuation
- 2010-09-13 MA MA33173A patent/MA32191B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR070430A1 (es) | 2010-04-07 |
| CA2715557A1 (en) | 2009-08-27 |
| CR11604A (es) | 2010-10-05 |
| EP2262784B1 (en) | 2014-04-16 |
| NI201000132A (es) | 2011-03-16 |
| CN102007108A (zh) | 2011-04-06 |
| ZA201005314B (en) | 2011-03-30 |
| NZ587380A (en) | 2011-09-30 |
| EP2262784A1 (en) | 2010-12-22 |
| KR20100123835A (ko) | 2010-11-25 |
| RU2010138577A (ru) | 2012-03-27 |
| ECSP10010409A (es) | 2010-09-30 |
| DOP2010000254A (es) | 2010-08-31 |
| US20100305088A1 (en) | 2010-12-02 |
| WO2009105435A1 (en) | 2009-08-27 |
| JP2011512412A (ja) | 2011-04-21 |
| BRPI0908815A2 (pt) | 2019-09-24 |
| CO6241113A2 (es) | 2011-01-20 |
| PE20091576A1 (es) | 2009-11-05 |
| MX2010008397A (es) | 2010-08-23 |
| AU2009215643A1 (en) | 2009-08-27 |
| SV2010003648A (es) | 2011-01-31 |
| MA32191B1 (fr) | 2011-04-01 |
| IL207597A0 (en) | 2010-12-30 |
| TW200948791A (en) | 2009-12-01 |
| US8268828B2 (en) | 2012-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0910182B8 (pt) | composto de fórmula (i), composição farmacêutica e uso de um composto | |
| UY33379A (es) | Compuestos de morfolina | |
| CL2009000171A1 (es) | Compuestos derivados de 1-oxa-3-azaespiro, antagonistas del receptor y5 de neuropeptido y (npy); composicion farmaceutica que comprende dicho compuesto; y uso para el tratamiento de trastornos de la alimentacion, trastornos de la bebida, obesidad y depresion. | |
| CL2011001464A1 (es) | Compuestos derivados de purina, agonistas del receptor cb2; composicion farmaceutica que los comprende; y uso del compuesto para tratar el dolor osteoartritico. | |
| CL2007001451A1 (es) | Compuestos derivados de [1,2,3]-tiazol-4-ilmetoxilo, agonista del receptor farnesoide x (fxr); composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar dislipidemia y enfermedades relacionadas. | |
| CL2011003147A1 (es) | Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer. | |
| CO6400170A2 (es) | Agosnistas y antagonistas del receptor s1p5 y métodos de uso de los mismos | |
| CL2011003085A1 (es) | Compuestos derivados de 1-(piperidin-4-il)-pirazol, moduladores de la actividad del receptor acoplado a proteina g, gpr 119; composicion farmaceutica; uso de los compuestos en el tratamiento de la diabetes o de una morbilidad asociada con dicha diabetes. | |
| CO6420342A2 (es) | Derivados de pirazol usados como antagonistas del receptor ccr4 | |
| CL2011000501A1 (es) | Composición farmacéutica que comprende un agonista de gpr119 en combinación con un inhibidor de dpp-4 seleccionado de un grupo definido; uso para prevenir y/o tratar enfermedades metabólicas, como resistencia insulinica, diabetes, sindrome metabolico, obesidad, hiperlipidemia, osteoporosis, entre otras. | |
| PA8638801A1 (es) | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| UY31863A (es) | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar | |
| CL2011000544A1 (es) | Compuestos derivados de benzamida n sustituida por heterociclo, ligandos de los receptores cannabinoides; composicion farmaceutica; y su uso para tratar el dolor, entre otras enfermedades. | |
| CO6351726A2 (es) | Compuestos pirazolicos 436 | |
| CL2011000087A1 (es) | Compuestos derivados de heteroarilo sustituido, inhibidores de los receptores dgat1; composicion farmaceutica; y su uso para tratar la diabetes tipo ll y obesidad. | |
| UY32926A (es) | Compuestos como antagonistas de los receptores de ácido lisofosfatídico | |
| CL2008003222A1 (es) | Peptidos con actividad antagonista de glucagon y composicion farmaceutica que los comprende, utiles para el tratamiento de la hiperglicemia, para suprimir el apetito, reducir el aumento de peso y para tratar el desgaste catabolico. | |
| BRPI0710232B8 (pt) | composto antagonista do receptor de il-8, composição farmacêutica que compreende o dito composto e uso do mesmo para o tratamento de uma doença mediada por quimiocina | |
| CR20110100A (es) | Nuevos derivados de sulfamida sustituida | |
| UY32036A (es) | Derivados de ciclohexil-amida, composiciones farmacéuticas que los contienen, su preparación y aplicaciones | |
| CL2009000116A1 (es) | Compuestos derivados de heterotriciclos sustituidos, antagonistas del receptor crf; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento de trastornos afectivos, depresion, ansiedad y sindrome del colon irritable. | |
| CL2008002430A1 (es) | Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc. | |
| CL2007003065A1 (es) | Compuestos derivados de benzodioxano, agonista 5ht2c, composicion farmaceutica que lois comprende; y sus uso en el tratamiento de un trastorno psicotico, ansiedad, depresion, trastorno bipolar, sindrome premenstrual, entre otros | |
| ECSP088584A (es) | Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl) | |
| CL2012002551A1 (es) | Combinacion farmaceutica que comprende por lo menos un 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol de fórmula (i) y por lo menos un antagonista de nmda; composicion farmaceutica; y uso para el tratamiento del dolor. |